April 15, 2008 / Add comment
PRNewswire News
The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical data presented today from an ongoing Phase II study extension.
Business Wire Technology News
To maintain a high level of asset protection for their clients, Add comment
For centuries the physics of cold interested only a few scientists, but by the early... Add comment
In the run-up to the New Hampshire primary, Mitt Romney, after failing to win in... Add comment
Spiders with personalities? It's not such a far-fetched idea, according to recent research; different populations... Add comment
acting as an antiseptic, or helping to soothe a sore throat. Jaffrey offers suggestions for... Add comment
IVA stands for Individual Voluntary Agreement Add comment
Clear Choice Health Plans, Inc. (OTCBB:CCHN) today announced its geographic expansion into Montana with the... Add comment
Dobbs Ferry, New York The Supreme Court is currently hearing arguments about the meaning of... Add comment
© 2008 Individual Benefits. All rights reserved. Contact Individual Benefits. Advertise. Privacy Policy